Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05375045
Recruiting Observational

Real-life Evaluation of the Safety and Performance of EUROTEKNIKA Dental Implants

NCT05375045 · tracked via the Priya Life Science France tracker
Sponsor
Euroteknika
Phase
Observational
Started
2022-03-25
Last updated
2022-05-16

Condition(s) studied

Edentulous Mouth

Investigational drug(s) / intervention(s)

dental implantation

dental implantation: an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.

Study summary

Real-life evaluation of the safety and performance of EUROTEKNIKA dental implants

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient aged 18 or over * Patient who has completed bone growth * Patient informed and agreeing to participate in the study * Partially or totally edentulous patient who will be implanted with the EUROTEKNIKA dental implant (for the prospective cohort) * Patient to benefit from the placement of an implant for the creation of a single crown (for the prospective cohort) * Patient implanted with the EUROTEKNIKA dental implant before 2017 (for the retrospective cohort) * Patient having benefited from the placement of an implant for the creation of a single crown (for the retrospective cohort) Exclusion Criteria: * Pregnant or breastfeeding women (for the prospective cohort) * Patient with bone disease in the cervico-facial region * Patient refusing to participate in the study * Patient with at least one contraindication to implantation (for the prospective cohort) * Patient to benefit from the placement of an implant with immediate or early loading (for the prospective cohort) * Patient to benefit from the placement of an implant for the support of the bridge, piles, attachment (for the prospective cohort) * Patient having benefited from the placement of an implant with immediate or early loading (for the retrospective cohort) * Patient having benefited from the placement of an implant for the support of the bridge, piles, attachment (for the retrospective cohort)

Primary outcome measure(s)

  • The success rate of tissue integration of the implant — 5 years after implantation
    Integration of the implant 5 years after implantation

Trial sites (1)

FacilityCityRegionStatus
Chu Clermont Ferrand Clermont-Ferrand France Recruiting

Other trials for the same condition

Multicentric Observational Study Confirming the Performance and Safety of the Axiom® BL X3 Implants Active, not recruiting
In Vivo Clinical Investigation of the Safety and Performance of Dental Implants TBR® Tissue Level Z1 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05375045 on ClinicalTrials.gov ↗ ← All trials in France